Intravenous thyrotropin releasing hormone vs placebo
Time from birth until death or full‐time ventilation · children with SMA types II and III
1 finding from 1 review
- no estimate extracted1 study · 9 participantsLow
Findings
What do systematic reviews say?
11 questions · 11 findings · 2 reviews · Neuromuscular
No studies found 3 · 27.3%GRADE not reported 1 · 9.1%Very low 3 · 27.3%Low 4 · 36.4%Moderate 0 · 0%High 0 · 0%
Brain‐derived neurotrophic factor vs placebo
Death · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes death compared with placebo (very low certainty).
1 finding from 1 review
- Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes onlyRR 0.67 [0.06, 7.85]1 study · 10 participantsVery low
Cerebrospinal fluid filtration vs plasma exchange
Death · patients with Guillain‐Barré syndrome
Cerebrospinal fluid filtration showed no clear difference in death compared with plasma exchange (low certainty).
1 finding from 1 review
- Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes onlyRR 1.18 [0.08, 17.42]1 study · 37 participantsLow
Tripterygium polyglycoside vs corticosteroids
Death · patients with Guillain‐Barré syndrome
1 finding from 1 review
- Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 43 participantsGRADE not reported
Eculizumab vs placebo
Death · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
Eculizumab showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
- Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes onlyRR 1.5 [0.08, 26.86]2 studies · 38 participantsLow
Interferon beta‐1a vs placebo
Death · patients with Guillain‐Barré syndrome
Interferon beta‐1a showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
- Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes onlyRR 1.5 [0.07, 32.29]1 study · 19 participantsLow
Brain‐derived neurotrophic factor vs placebo
Death or disability after 12 months · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes death or disability after 12 months compared with placebo (very low certainty).
1 finding from 1 review
- Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes onlyRR 1.33 [0.17, 10.25]1 study · 10 participantsVery low
Cerebrospinal fluid filtration vs plasma exchange
Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Tripterygium polyglycoside vs corticosteroids
Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Interferon beta‐1a vs placebo
Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Eculizumab vs placebo
Death or disability after 12 months In the absence of data at 12 months, we report the outcome at 6 months · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
It is very uncertain whether eculizumab changes death or disability after 12 months In the absence of data at 12… compared with placebo (very low certainty).
1 finding from 1 review
- Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes onlyRR 1.21 [0.15, 10.11]2 studies · 38 participantsVery low